Skip to main navigation Skip to search Skip to main content

Hairy Cell Leukemia

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Over the past five decades, progress in the treatment of patients with hairy cell leukemia (HCL) has led to a significant change in the natural history of the disease, with the majority of patients achieving complete remissions with the currently available treatment strategies and with survival curves similar to those for appropriate age-matched individuals without the disease. At the same time, new technologies are allowing better understanding of the molecular mechanisms responsible for the pathogenesis of this as well as other indolent lymphoid neoplasms. Several studies, using modern techniques with different sensitivities, have demonstrated the persistence of minimal residual disease (MRD) after therapy with nucleoside analogs in the majority of patients. However, it is not clear whether such MRD would invariably lead to leukemia recurrence or what level of MRD can predict relapse. The role of monoclonal antibodies, naked or conjugated with toxins, in the management of HCL and their ability to eradicate MRD is under investigation. Whether such strategies of chemo-immunotherapy would lead to further improvements in the outcome of patients with HCL would need to be further investigated.

Original languageEnglish (US)
Title of host publicationLeukemias
Subtitle of host publicationPrinciples and Practice of Therapy
PublisherWiley-Blackwell
Pages339-347
Number of pages9
ISBN (Print)9781405182355
DOIs
StatePublished - Jan 4 2011

Keywords

  • Hairy cell leukemia
  • Pathogenesis
  • Therapy

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Hairy Cell Leukemia'. Together they form a unique fingerprint.

Cite this